[HTML][HTML] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
D Planchard, PA Jänne, Y Cheng… - … England Journal of …, 2023 - Mass Medical Soc
Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
[HTML][HTML] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
SS Ramalingam, J Vansteenkiste… - … England Journal of …, 2020 - Mass Medical Soc
Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
[HTML][HTML] Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
JC Soria, Y Ohe, J Vansteenkiste… - New England journal …, 2018 - Mass Medical Soc
Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
[HTML][HTML] Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment …
K Tanaka, H Asahina, J Kishimoto, Y Miyata… - European Journal of …, 2021 - Elsevier
Background Osimertinib is now a standard treatment for patients with previously untreated
EGFR-mutated advanced non–small cell lung cancer (NSCLC). We here investigated …
EGFR-mutated advanced non–small cell lung cancer (NSCLC). We here investigated …
Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study
Y Cheng, Y He, W Li, H Zhang, Q Zhou, B Wang… - Targeted Oncology, 2021 - Springer
Background In the global FLAURA study, first-line osimertinib, a third-generation irreversible
tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly …
tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly …
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
SS Ramalingam, JCH Yang, CK Lee… - Journal of Clinical …, 2018 - ascopubs.org
Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …
Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
Osimertinib is the only Food and Drug Administration‐approved third‐generation epidermal
growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was …
growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was …
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
M Santarpia, A Liguori, N Karachaliou… - Lung Cancer: Targets …, 2017 - Taylor & Francis
The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
[HTML][HTML] Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies
V Di Noia, A D'aveni, E D'argento, S Rossi… - ESMO open, 2021 - Elsevier
Highlights•Acquired resistance mechanisms to osimertinib can be EGFR dependent or
independent.•First-and fourth-generation EGFR-TKIs are able to overcome EGFR …
independent.•First-and fourth-generation EGFR-TKIs are able to overcome EGFR …
[HTML][HTML] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non …
kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR-mutant non …